Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021

Sumitomo Dainippon Pharma will abandon all of its ongoing PI and PII clinical studies of its investigational anticancer agent napabucasin after a flop in a closely watched global PIII study for colorectal cancer. The Osaka drug maker announced the termination...read more